Navigation Links
Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates

Cleveland Clinic Researchers Highlight the Need For More Women to

Participate in Clinical Trials

ORLANDO, Fla., Nov. 6 /PRNewswire-USNewswire/ -- Cleveland Clinic researchers have recently found that women remain a significant minority in cardiovascular randomized controlled trials funded by the National Heart, Lung and Blood Institute (NHLBI).

Lead Author, Esther S.H. Kim, M.D., M.P.H., Senior Author Venu Menon, M.D., and a team of Cleveland Clinic researchers searched the National Institutes of Health's (NIH) database of clinical trials ( for studies funded by the NHLBI with outcomes of stroke, heart attack, or death. The studies were published between 1997 and 2006.

Results of "Enrollment of Women in NHLBI Funded Cardiovascular Randomized Controlled Trials Fail to Meet Current Federal Mandates for Equal Inclusion" were presented at the American Heart Association's 27th Annual Scientific Session currently underway in Orlando, Fla.

"Despite federal mandates, NIH policies, and ongoing NIH scrutiny, enrollment of women remains inadequate in NIH-sponsored, phase III-IV, cardiovascular randomized, controlled trials," Dr. Kim said. "In addition, there has been little change in the proportion of women enrolled in these trials over the past decade."

This under-representation of women subjects was recognized over a decade ago and resulted in a NIH mandate for the inclusion of women in clinical research. Cleveland Clinic researchers sought to evaluate the impact of these guidelines on federally funded cardiovascular randomized controlled trials.

Women account for half the cardiovascular mortality in the United States, but it is unknown why more women do not sign up for these clinical trials. Increased participation of women in acute and high-risk cardiovascular, randomized, controlled trials remains a priority and deserves ongoing scrutiny, Dr. Kim said.

She suggests that educational efforts at the level of the patient, study site, and investigator are needed to increase participation of women. Additional research into why so few women participate in clinical trials is also warranted, she said.

Of the 982 NHLBI-funded cardiovascular studies examined, 141 were phase III or IV randomized controlled trials in adults, 53 had outcomes of interest, and only 19 were published between 1997 and 2006. The research spanned 19 trials: nine acute, eight high risk, eight coronary artery disease, three congestive heart failure and seven electrophysiology trials, in addition to one hypertension trial. Researchers observed no increase in the enrollment of women between 1997 and 2006 (mean 27%, range 10-47%). There was no association between enrollment and acuity, type of disease, or level of risk.

Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Approximately 1,800 full-time salaried physicians and researchers at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2006, there were 3.1 million outpatient visits to Cleveland Clinic. Patients came for treatment from every state and from more than 80 countries. There were more than 53,000 hospital admissions to Cleveland Clinic in 2006. Cleveland Clinic's Web site address is

SOURCE Cleveland Clinic
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):